Proteinuria should be used as a surrogate in CKD. (Q37990717)

26 August 2017

title

Proteinuria should be used as a surrogate in CKD. (English)

1 reference

26 August 2017

3

1 reference

26 August 2017

2

Piero Ruggenenti

1 reference

26 August 2017

1

Paolo Cravedi

1 reference

26 August 2017

language of work or name

English

0 references

publication date

6 March 2012

1 reference

Nature Reviews Nephrology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

301-306

1 reference

Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Kidney failure stabilizes after an increase over 2 decades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Time to abandon microalbuminuria?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Early renal function decline in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

31 March 2020

12 December 2020

Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

How does proteinuria cause progressive renal damage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Paracrine stimulation of human renal fibroblasts by proximal tubule cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Alternative pathway activation of complement by cultured human proximal tubular epithelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Risk of developing end-stage renal disease in a cohort of mass screening.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Pathophysiology of Progressive Nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Renal protective effect of enalapril in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Progression, remission, regression of chronic renal diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Sodium intake, ACE inhibition, and progression to ESRD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Remission of nephrotic-range albuminuria in type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

31 March 2020

12 December 2020

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Statins for improving renal outcomes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Role of remission clinics in the longitudinal treatment of CKD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Preventing microalbuminuria in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

High Level of Proteinuria During Treatment With Renin—Angiotensin Inhibitors Is a Strong Predictor of Renal Outcome in Nondiabetic Kidney Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.42

Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus

31 March 2020

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?

1 reference

12 December 2020

Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN)

1 reference

12 December 2020

Current concepts in proteinuria

1 reference

12 December 2020

Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.42

1 reference

Dimensions Publication ID

26 August 2017

1013469084

0 references

1 reference